We’re excited to attend the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 in Chicago. Learn more.
Complete solutions for complex challenges
QIAGEN at AMP Europe 2018 Video: NGS Assay Development Lead Dr. Simon Hughes discusses recent studies for the QIAact Lung All in One panel and the Myeloid panel for the GeneReader NGS workflow at AMP Europe 2018.
Watch Dr. Atil Bisgil from Cukurova University, Turkey talk about expanding to microbiome research with the GeneReader NGS System. He discusses the pressures faced in a laboratory focused on next generation sequencing and research, looking toward the future of high-throughput NGS testing and expanding to microbiome research with the GeneReader.
Today, patients want to know more about new treatment options as they come to market, and be more engaged in their treatment decisions, receive more personalized healthcare and, ultimately, feel confident that they’re receiving the best treatment. This means that launching new products in this evolving environment will require launch teams from pharmaceutical companies to… Read article →
An article published on WBUR’s CommonHealth blog opens a window into liquid biopsy, also referred to as blood biopsy, in its current and future state. The article discusses how this rapidly-evolving technology has the potential to transform the way we detect and treat cancer. The technology of liquid biopsy is rapidly evolving, but still has… Read article →
Recent statistics have placed lung cancers as the second most common form of cancer and by far the leading cause of cancer death in both men and women (1). With poor survival rates using current treatments, gaining a better understanding of the underlying molecular drivers of lung cancers has been the focus of numerous research… Read article →
Expanded use of ipsogen test provides diagnostic testing needs for all myeloproliferative neoplasms in line with the latest WHO guidelines Hilden, Germany, and Germantown, Maryland, January 23, 2018 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the… Read article →
QIAGEN had the pleasure of taking part in an NGS Bioinformatics Challenge run by the German Society for Pathology on the 9th and 10th of November in Halle, Germany. Three commercial organizations were supplied with vcf files from twelve samples sequenced using Illumina MiSeq™ Systems and the IonTorrent platform at Erlangen, Cologne Berlin. The identity… Read article →
Studies presented at AMP Global conference in Berlin reaffirm powerful analytical performance and ease of use for the world’s first complete Sample to Insight NGS solution Hilden, Germany, April 3, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced further validation of the GeneReader NGS System with the publication of five new… Read article →
New biomarker test – the fifth QIAGEN oncology test with FDA clearance in the U.S. – designed to aid diagnosis of patients suspected of having Polycythemia Vera form of blood cancer Germantown, Maryland, and Hilden, Germany, March 29, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its ipsogen® JAK2 RGQ… Read article →
ALK gene rearrangements have been described in 3–5% of lung adenocarcinomas (ADC), and the presence of dysregulated ALK has been described in at least 18 cancer types (reviewed in 1). Since lung cancer is a common type of cancer, an estimated 70,000 cases of non-small cell lung cancer (NSCLC) which have ALK genomic alterations occur… Read article →
Pyrosequencing is reported as the ideal method for MGMT methylation analysis, and is validated for use in clinical practice. Methylation of the O6-methylguanine- DNA-methyltranferase (MGMT) promoter region is associated with several cancer types, including colorectal cancer, lung cancer, lymphoma and glioblastoma. MGMT promoter methylation is a powerful predictive biomarker of positive response to temozolomide, a… Read article →